Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts.

Details

Serval ID
serval:BIB_3F864F08541F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Microsatellite instability and sex differences in resectable gastric cancer - A pooled analysis of three European cohorts.
Journal
European journal of cancer
Author(s)
Quaas A., Biesma H.D., Wagner A.D., Verheij M., van Berge Henegouwen M.I., Schoemig-Markiefka B., Pamuk A., Zander T., Siemanowski J., Sikorska K., Egthuijsen JMP, Meershoek-Klein Kranenbarg E.M., van de Velde CJH, Buettner R., Alakus H., Cats A., Ylstra B., van Laarhoven HWM, van Grieken NCT
ISSN
1879-0852 (Electronic)
ISSN-L
0959-8049
Publication state
Published
Issued date
09/2022
Peer-reviewed
Oui
Volume
173
Pages
95-104
Language
english
Notes
Publication types: Journal Article ; Meta-Analysis
Publication Status: ppublish
Abstract
Biological sex differences in cancer are increasingly acknowledged. Here, we examined these differences in clinicopathological characteristics and survival in microsatellite instability (MSI)-high and microsatellite stable (MSS) gastric cancer (GC).
We analysed MSI status by polymerase chain reaction (PCR) and/or mismatch repair (MMR) status by immunohistochemistry in a pooled analysis of individual patient data from one retrospective cohort from Cologne, and the randomised phase III clinical trials D1/D2 and CRITICS. All patients had resectable adenocarcinoma of the stomach and/or gastro-oesophageal junction. Patients were treated with either surgery only or perioperative chemo(radio)therapy.
MSI and/or MMR analyses on 1307 tumours resulted in 1192 (91.2%) MSS and/or MMR proficient (MMRP) [median age, 65 years; 759 males (63.7%); 619 treated with surgery only (51.9%)], and 115 (8.8%) MSI-high [median age, 69 years; 67 males (58.3%); 76 treated with surgery only (66.1%)] GC cases. Males had shorter overall survival (OS) than female MSI-high GC (5-year OS 34.7% vs. 69.7%; hazard ratio (HR) 2.68, 95%CI 1.60 to 4.49; p < 0.001). Females with MSI-high had longer OS than those with MSS/MMRP GC (HR 0.61, 95%CI 0.41 to 0.92; p = 0.02). Males with MSI-high did not have longer OS than those with MSS/MMRP GC (HR 1.26, 95%CI 0.94 to 1.69; p = 0.12).
MSI-high GC males had a significantly worse prognosis compared to their female counterparts in three independent cohorts. In addition, the favourable prognostic value of MSI was only seen in females and not in males. These observations emphasise the need to consider sex differences in prognosis and treatment effects in oncology.
The CRITICS trial is registered at ClinicalTrials.gov, number NCT00407186; EudraCT, number 2006-004130-32; and CKTO, 2006-02.
Keywords
Aged, DNA Mismatch Repair, Female, Humans, Male, Microsatellite Instability, Prognosis, Retrospective Studies, Sex Characteristics, Stomach Neoplasms/drug therapy, Stomach Neoplasms/genetics, Stomach Neoplasms/surgery, Gastric carcinoma, Microsatellite instability (MSI-high), Sex differences
Pubmed
Open Access
Yes
Create date
03/08/2022 9:00
Last modification date
17/10/2022 5:40
Usage data